Unibest

Pharmaceutical intermediates

Risdiplam Intermediates

3 pharmaceutical intermediates for Risdiplam. Indication: Spinal Muscular Atrophy (SMA).

提交项目All intermediates

About Risdiplam

Originator
Ptc Therapeutics Inc
Indication
Spinal Muscular Atrophy (SMA)
Approved Date
08/07/2020
NCE Patent
08/07/2025
DS/DP
02/08/2033

Available intermediates

3 intermediates currently listed for Risdiplam. Request specifications, documentation or a quotation for any item below.

Risdiplam intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one1449598-85-9//
4-Boc-4,7-diazaspiro[2.5]octane674792-08-6//
2,8-Dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine1825352-86-0//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenib

Building toward Risdiplam?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →